drugset
drugset / Trial / NCT01213160

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

NCT01213160 ↗

Phase 1 Completed 40 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.

Timeline

Start
2010-11
Primary completion
2013-06
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexagratinib Small molecule 40 mg Oral
Subject Fexagratinib Small molecule 80 mg Oral
Subject Fexagratinib Small molecule 120 mg Oral
Subject Fexagratinib Small molecule 160 mg Oral

Indications

high grade malignant neoplasm